Fast, Lasting, Powerful Pain Relief and Much More Based on Industry-Leading Clinical Research Results
When nothing else works. As your first line of defense. Target the underlying cause.
In various clinical trials, D'OXYVA® (deoxyhemoglobin vasodilator) has achieved over 90% reduction of all sorts of chronic pain either the same day or in a few days, even from 8 to 1 on the Visual Analog Scale (VAS).
Besides clinical results, new and long-term users of D'OXYVA reported relief of persistent long-term chronic pain associated with neuropathy, chemotherapy and radiation therapy, non-healing wounds, arthritis, migraine headaches, and the lower back in 2 to 7 days.
Impaired tissue perfusion denies oxygen and blood flow where it is needed most, preventing the delivery of nutrients, natural pain relief, and slowing the healing process. Few people, however, suffer as much from poor circulation as those with high blood sugar, arthritis, osteoarthritis, venous insufficiency, and cardiovascular complications do.
Poor circulation in these people can result in high blood pressure, hypertension, neuropathy pain, ulcers, and even necrosis. Restrictions in this form of circulation impede the flow of antibodies, white blood cells and platelets, and rob the skin and tissues of oxygen and much needed nutrients. Researchers are continuously seeking out solutions that reduce these symptoms, and recent clinical research has revealed a uniquely promising and affordable possibility.
non-invasive solution has demonstrated strengthening the body’s natural healing foundation: the autonomic nervous system (parasympathetic nerve activity) and the microcirculatory system.
Microcirculation dysfunction is increasingly regarded by the mainstream medical, scientific, cosmetic, and alternative health care community as the underlying cause of nearly all health complications for both the young and elderly.
D'OXYVA® (deoxyhemoglobin vasodilator) has been demonstrating fast, lasting, and powerful pain relief and numerous significant health benefits in record time and has been reviewed, studied, and used at institutions around the world such as Penn State University, Florida State University, Valley Presbyterian Hospital, Hospital Kuala Lumpur, Airlangga University, Chulalongkorn University, University of Szeged, National Taipei University and others.
Featured Free White Paper: 'Industry-Leading Noninvasive Transdermal Microcirculatory Technology for Rapid Closure of Complex Wounds with Significant Pain Relief'
Source: Prof. Judy M. Delp, PhD, Florida State University U.S.A (June 2013)
Industry-Leading Human Clinical Trial Results Show Unmatched Circulation Improvements
1. Improved microcirculation (Skin Perfusion Pressure) in a statistically significant manner in every subject by about 15-100% (majority well above 40%).
2. Improvement in blood flow peaked uniformly within an hour after a single 5-minute delivery on the thumb, and subsequently lasted for over 4 hours.
3. All enrolled subjects responded positively without adverse events after being monitored for a year after the study.
The above results have been successfully reproduced by other studies and in various test reports with D'OXYVA, victims of neuropathy, peripheral vascular complications, bodily injury, surgical complications, and various forms of pain reported significant reduction in symptoms and pain in 9 out of 10 cases, typically, from an 8 to 1 on the Visual Analog Scale (VAS) within a week of once a day use of just 5 minutes (press release).
Furthermore, 9 out of 10 users reported significant long-term health benefits, after only 6 to 8 weeks of regular daily use (press release).
D'OXYVA is a Non-Invasive Transdermal Delivery (NTD), Non-Significant Risk (NSR) device, and Circularity Healthcare is conducting high-quality, cutting-edge clinical trials with leading institutions, researches, and health practitioners around the world to establish evidence for a wide variety of scientific and clinical outcomes with D'OXYVA. Please contact us to participate in Circularity's Center of Excellence (COE) program.
A Variety of Significant Outcomes Through Improved Tissue Perfusion
As the above summary abstract presented at the 2013 Diabetic Foot Global Conference describes, in a pilot study all subjects received a painless, five-minute D'OXYVA delivery through their thumb and their Skin Perfusion Pressure (i.e., microcirculation) was measured periodically for four hours afterward.
Subjects suffering from high blood sugar have reported
neuropathy relief minutes after D'OXYVA was administered.
All subjects recorded significant increases in Skin Perfusion Pressure (i.e., microcirculation). In fact, nearly 33% increase on average from absolute baseline during the four hours after administration, which is groundbreaking in its field. Both systolic and diastolic blood pressures were significantly reduced over thirty to sixty minutes and sustained over four hours by an average 25 points from absolute baseline.
Circularity has assembled a Scientific Advisory Board that includes domestic and international medical thought-leaders in the field of
diabetic relief, wound healing, microvascular physiology, neurobiology, endocrinology, amputation prevention, vascular surgery, and cardiovascular physiology.
These clinical and academic physicians, with a combined total of thousands of publications, have been tasked with investigating the D'OXYVA® (deoxyhemoglobin vasodilator) delivery system, and ascertaining the potential benefits of combating destructive symptoms of high blood sugar and other health complications through boosting microcirculation.
They were asked investigating the administration of gas molecules (gasotransmitters) already found in our bodies naturally in a non-traditional way. Rather than working through inhalation or needle injection, D'OXYVA is administered directly on the skin. The resulting CO2 saturation in the vapor sprayed on the skin by D'OXYVA has been detected to induce long lasting and significant vasodilation and the Bohr effect. This increased perfusion in the capillary microcirculation locally on the delivery site and elsewhere as applied.
More clinical trials are under way to determine additional benefits, but these results thus far are extremely promising and indicating treatment for a variety of disease states related to deficiencies of blood circulation, autonomic nervous system, and cellular and tissue oxygenation.
Independent References Online